Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Slide 70 The GLP-1 segment accounts for around 11% of total diabetes care market value in Europe European GLP-1 market VictozaⓇ exenatide VictozaⓇ value market share in Europe VictozaⓇ exenatide - dulaglutide other ▪dulaglutide Share of total other GLP-1 value diabetes care market share market 10% 100% 8% 80% 6% 60% + 4% 40% +2% 20% 0% 0% Nov 2017 Nov 2012 GLP-1 value in bDKK 7 6 CAGR value¹: 15.2% 5 4 3 2 1 0 Nov 2012 1 CAGR for 5-year period Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 value figures (DKK) changing diabetes® Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 value figures (DKK) 58% 26% 13% 3% Nov 2017 novo nordisk

View entire presentation